AU Patent

AU2012212142A1 — Methods of using ALK inhibitors

Assigned to Novartis AG · Expires 2013-08-15 · 13y expired

What this patent protects

The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK

USPTO Abstract

The invention provides methods for using compounds of Formula (I) for treating an EML4-ALK

Drugs covered by this patent

Patent Metadata

Patent number
AU2012212142A1
Jurisdiction
AU
Classification
—
Expires
2013-08-15
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.